person · Reporting owner

Miller Steven B

Disclosed activity across 3 companies

Tapewire entity: 49129
SEC CIK: 0001599611

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BrightSpring Health Services, Inc.BTSG · Entity 3469	Director	May 05, 2026	May 07, 2026
Cigna GroupCI · Entity 550	EVP, Chief Clinical Officer	February 26, 2021	March 03, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BrightSpring Health Services, Inc.

Report date May 05, 2026 · Filed May 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,106	Reported balance After 2026-05-05 transaction · row 1 1 source row Row 1 · 2026-05-05 · Grant · Acquired 4,983 · Balance 23,106 F1: On May 5, 2026, the Reporting Person was granted restricted stock units ("RSUs") which fully vest on May 5, 2027. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2026, the Reporting Person was granted restricted stock units ("RSUs") which fully vest on May 5, 2027. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

Cigna Group

Report date February 26, 2021 · Filed March 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	28,439	Ending reported balance After 2021-02-26 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2021-02-26 · Grant · Acquired 3,831 · Balance 31,377 F1: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Row 2 · 2021-02-26 · Tax withholding · Disposed 383 · Balance 30,994 F2: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Row 3 · 2021-02-26 · Tax withholding · Disposed 840 · Balance 30,154 F3: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Row 4 · 2021-02-26 · Tax withholding · Disposed 1,715 · Balance 28,439 F4: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.

F2: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

F3: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units.

F4: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Express Scripts Holding Co.

Report date December 20, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 43,800 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.05 · Expires 2019-02-27	Direct	Reported balance After 2018-12-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 2,325 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.05 · Expires 2019-02-27	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 26,169 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.17 · Expires 2020-03-06	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 17,507 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2021-03-05	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 20,304 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.83 · Expires 2025-03-04	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 22,171 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.82 · Expires 2025-12-01	Direct	Reported balance After 2018-12-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-20 · Disposition to issuer · Disposed 5,818 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.57 · Expires 2026-03-09	Direct	Reported balance After 2018-12-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-20 · Disposition to issuer · Disposed 36,551 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.62 · Expires 2027-03-08	Direct	Reported balance After 2018-12-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-12-20 · Disposition to issuer · Disposed 41,347 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-12-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-12-20 · Disposition to issuer · Disposed 2,008.0446 · Balance 0 F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.

F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock.

F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 05, 2026 Filed May 7, 2026 22:31 UTC	BrightSpring Health Services, Inc. BTSG · Entity 3469	GrantCommon Stock	4,983	$0.00	$0.00	Disclosure SEC source: 0000908834-26-000217 · form4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,106 F1 · kind: On May 5, 2026, the Reporting Person was granted restricted stock units ("RSUs") which fully vest on May 5, 2027. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. Read SEC document
November 05, 2025 Filed Nov 6, 2025 21:06 UTC	BrightSpring Health Services, Inc. BTSG · Entity 3469	Tax withholdingCommon Stock	4,497	$32.68	$146,961.96	Disclosure SEC source: 0000908834-25-000319 · form4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,123 F1 · shares: Represents shares of the Issuer's common stock withheld by the Issuer to satisfy withholding taxes due in connection with the vesting of 10,708 restricted stock units at a net settlement price equal to the closing stock price on November 5, 2025. Read SEC document
May 05, 2025 Filed May 7, 2025 20:09 UTC	BrightSpring Health Services, Inc. BTSG · Entity 3469	GrantCommon Stock	11,912	$0.00	$0.00	Disclosure SEC source: 0000908834-25-000144 · form4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,620 F1 · kind: On May 5, 2025, the Reporting Person was granted restricted stock units ("RSUs") which fully vest on May 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. F2 · balance_after: Includes 10,708 shares of the Issuer's common stock underlying RSUs which fully vest on November 5, 2025 and 11,912 shares of the Issuer's common stock underlying RSUs which fully vest on May 5, 2026. Read SEC document
November 05, 2024 Filed Nov 8, 2024 23:18 UTC	BrightSpring Health Services, Inc. BTSG · Entity 3469	GrantCommon Stock	10,708	$0.00	$0.00	Disclosure SEC source: 0000908834-24-000302 · form4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,708 F1 · kind: On November 5, 2024, the Reporting Person was granted restricted stock units ("RSUs") which fully vest on November 5, 2025. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. F2 · balance_after: Includes 10,708 shares of the Issuer's common stock underlying RSUs, as described in footnote 1 herein. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,715	$210.31	$360,681.65	Disclosure SEC source: 0001225208-21-004366 · doc4.xml · nonDerivative · entry 4 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,439 F4 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	840	$209.90	$176,316.00	Disclosure SEC source: 0001225208-21-004366 · doc4.xml · nonDerivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,154 F3 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	383	$210.31	$80,548.73	Disclosure SEC source: 0001225208-21-004366 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,994 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	3,831	$0.00	$0.00	Disclosure SEC source: 0001225208-21-004366 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,377 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:22 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	6,134	$0.00 Strike: $213.80	$0.00	Disclosure SEC source: 0001225208-21-003975 · doc4.xml · derivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,134 Underlying: Common Stock, $.01 Par Value · 6,134 shares Expires 2031-02-24 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:22 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,287	$0.00	$0.00	Disclosure SEC source: 0001225208-21-003975 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,546 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document
February 04, 2021 Filed Feb 8, 2021 23:23 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	622	$210.53	$130,949.66	Disclosure SEC source: 0001225208-21-001888 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,259 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
January 07, 2021 Filed Jan 8, 2021 22:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	777	$0.00 Strike: $160.66	$0.00	Disclosure SEC source: 0001225208-21-000701 · doc4.xml · derivative · entry 5 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 777 shares Expires 2021-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · derivative.exercise_date: This option was granted on March 5, 2014. The option vested in three equal annual installments on February 28, 2015, February 28, 2016, and February 28, 2017. Read SEC document
January 07, 2021 Filed Jan 8, 2021 22:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	777	$160.66	$124,834.61	Disclosure SEC source: 0001225208-21-000701 · doc4.xml · nonDerivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document
January 06, 2021 Filed Jan 8, 2021 22:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	8,972	$0.00 Strike: $160.66	$0.00	Disclosure SEC source: 0001225208-21-000701 · doc4.xml · derivative · entry 4 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777 Underlying: Common Stock, $.01 Par Value · 8,972 shares Expires 2021-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · derivative.exercise_date: This option was granted on March 5, 2014. The option vested in three equal annual installments on February 28, 2015, February 28, 2016, and February 28, 2017. Read SEC document
January 06, 2021 Filed Jan 8, 2021 22:31 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	8,972	$210.00	$1,884,120.00	Disclosure SEC source: 0001225208-21-000701 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,104 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document
January 06, 2021 Filed Jan 8, 2021 22:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	8,972	$160.66	$1,441,462.16	Disclosure SEC source: 0001225208-21-000701 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:47 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,426	$182.94	$260,872.44	Disclosure SEC source: 0001225208-20-003962 · doc4.xml · nonDerivative · entry 4 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,104 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:47 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	858	$179.41	$153,933.78	Disclosure SEC source: 0001225208-20-003962 · doc4.xml · nonDerivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,530 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:47 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,178	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003962 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,388 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2020 Filed Mar 3, 2020 01:47 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	149	$185.76	$27,678.24	Disclosure SEC source: 0001225208-20-003962 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,210 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	5,243	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001225208-20-003811 · doc4.xml · derivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,243 Underlying: Common Stock, $.01 Par Value · 5,243 shares Expires 2030-02-26 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,433	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003811 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,359 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 11, 2020 Filed Feb 13, 2020 23:07 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	8,406	$0.00 Strike: $121.14	$0.00	Disclosure SEC source: 0001225208-20-002233 · doc4.xml · derivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 8,406 shares Expires 2020-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on March 6, 2013. The option vested in three equal annual installments on February 28, 2014, February 28, 2015 and February 28, 2016. Read SEC document
February 11, 2020 Filed Feb 13, 2020 23:07 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	7,145	$212.15	$1,515,838.90	Disclosure SEC source: 0001225208-20-002233 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,926 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $211.546 to $212.46 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 11, 2020 Filed Feb 13, 2020 23:07 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	8,406	$121.14	$1,018,278.46	Disclosure SEC source: 0001225208-20-002233 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2019 Filed Mar 4, 2019 23:39 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,881	$174.44	$328,121.64	Disclosure SEC source: 0001225208-19-004413 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,665 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,116	$0.00 Strike: $110.47	$0.00	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 8 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,116 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents options that were automatically exercised immediately prior to their expiration. F6 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	5,179	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 7 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,179 Underlying: Common Stock, $.01 Par Value · 5,179 shares Expires 2029-02-27 F5 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	12,566	$0.00 Strike: $110.47	$0.00	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 6 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 12,566 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents options that were automatically exercised immediately prior to their expiration. F4 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Options vested in three equal annual installments on February 28, 2013, February 28, 2014, and February 28, 2015. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	9,135	$180.72	$1,650,877.20	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 5 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,546 F2 · shares: Represents shares tendered to Company to cover payment of exercise price and tax liability due upon exercise of stock option. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	812	$180.72	$146,744.64	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 4 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,681 F2 · shares: Represents shares tendered to Company to cover payment of exercise price and tax liability due upon exercise of stock option. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,116	$110.47	$123,289.99	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,500	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,377 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:24 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	12,566	$110.47	$1,388,227.59	Disclosure SEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 04, 2019 Filed Feb 6, 2019 00:05 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	4,179	$0.00	$0.00	Disclosure SEC source: 0001225208-19-001829 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,311 F1 · balance_after: Total holdings were increased by one share of common stock due to a rounding error on the Form 4 report that was filed on December 26, 2018. Read SEC document
February 01, 2019 Filed Feb 6, 2019 00:05 UTC	Cigna Group CI · Entity 550	GrantPhantom Stock Units · Derivative	154.6726	$194.06 Strike: $0.00	$30,015.76	Disclosure SEC source: 0001225208-19-001829 · doc4.xml · derivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118.6726 Underlying: Common Stock, $.01 Par Value · 154.6726 shares Expires not disclosed F2 · security: Phantom Stock Units credited under Express Scripts Executive Deferred Compensation Plan. F3 · derivative.exercise_price: Upon distribution, each Phantom Stock Unit converts to one share of Cigna Corporation Common Stock. F4 · derivative.exercise_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. F4 · derivative.expiration_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerPhantom Stock Units · Derivative	2,008.0446	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 10 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 2,008.0446 shares Expires not disclosed F4 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5 · derivative.exercise_price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6 · kind: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F7 · derivative.exercise_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F7 · derivative.expiration_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	41,347	$0.00 Strike: $67.62	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 9 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 41,347 shares Expires 2027-03-08 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	36,551	$0.00 Strike: $69.57	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 8 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 36,551 shares Expires 2026-03-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	5,818	$0.00 Strike: $86.82	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 7 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,818 shares Expires 2025-12-01 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	22,171	$0.00 Strike: $84.83	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 6 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 22,171 shares Expires 2025-03-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	20,304	$0.00 Strike: $77.15	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 5 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 20,304 shares Expires 2021-03-05 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	17,507	$0.00 Strike: $58.17	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 4 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 17,507 shares Expires 2020-03-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	26,169	$0.00 Strike: $53.05	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 3 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 26,169 shares Expires 2019-02-27 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative	2,325	$0.00 Strike: $53.05	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · derivative · entry 2 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 2,325 shares Expires 2019-02-27 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document
December 20, 2018 Filed Dec 21, 2018 16:58 UTC	Express Scripts Holding Co. ESRX · Entity 161583	Disposition to issuerCommon Stock	43,800	$0.00	$0.00	Disclosure SEC source: 0000950138-18-000691 · edgar.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:18 UTC	Cigna Group CI · Entity 550	GrantPhantom Stock Units · Derivative	964	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 13 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964 Underlying: Common Stock, $0.01 Par Value · 964 shares Expires not disclosed F10 · security: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F1 · derivative.exercise_price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · derivative.exercise_price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F10 · derivative.exercise_price: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F10 · price: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F10 · derivative.exercise_date: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F10 · derivative.expiration_date: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:18 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	19,854	Not disclosed Strike: $140.82	Not disclosed	Disclosure SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 12 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,854 Underlying: Common Stock, $0.01 Par Value · 19,854 shares Expires 2027-03-08 F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F9 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase shares of New Cigna Common Stock, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:18 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	17,551	Not disclosed Strike: $144.88	Not disclosed	Disclosure SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 11 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,551 Underlying: Common Stock, $0.01 Par Value · 17,551 shares Expires 2026-03-09 F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F8 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase shares of New Cigna Common Stock, with the remaining one-third of the option vesting on February 28, 2019. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:18 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	2,793	Not disclosed Strike: $180.80	Not disclosed	Disclosure SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 10 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 Underlying: Common Stock, $0.01 Par Value · 2,793 shares Expires 2025-12-01 F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.